ReviewJournal of immunology research2015
Harnessing the Microbiome to Enhance Cancer Immunotherapy.
Review in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Microbiome and Response to Therapy in Triple Negative Breast Cancer: A Systematic Review.Oncology research · 2026Pooled it
- Exploring the role of inflammatory regulatory effects of probiotics as adjuvants in cancer development management with considering possible challenges: a comprehensive review.Inflammopharmacology · 2025Review
- Review
- Harnessing the microbiome to improve clinical outcomes for cancer, transplant, and immunocompromised patients in the intensive care unit (ICU).Frontiers in cellular and infection microbiology · 2025Review
- Advancements and challenges in CAR T cell therapy in autoimmune diseases.Nature reviews. Rheumatology · 2024Review
- The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer.Cancers · 2023Review
- Harnessing the Microbiome: A Comprehensive Review on Advancing Therapeutic Strategies for Rheumatic Diseases.Cureus · 2023Review
- Probiotics formulation and cancer nanovaccines show synergistic effect in immunotherapy and prevention of colon cancer.iScience · 2023Article
- IntegratedNAR genomics and bioinformatics · 2023Article
- Small Molecules as Toll-like Receptor 4 Modulators Drug andBiomedicines · 2022Article
- A Review of the Role of Oral Microbiome in the Development, Detection, and Management of Head and Neck Squamous Cell Cancers.Cancers · 2022Review
- Engineered implantable vaccine platform for continuous antigen-specific immunomodulation.Biomaterials · 2022Article
- Review
- Review
- Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).British journal of cancer · 2021Observational
- Exploring the Modulatory Effects of Gut Microbiota in Anti-Cancer Therapy.Frontiers in oncology · 2021Review
- Strategies for Remodeling the Tumor Microenvironment Using Active Ingredients of Ginseng-A Promising Approach for Cancer Therapy.Frontiers in pharmacology · 2021Review
- Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.International journal of molecular sciences · 2020Review
- Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance.Journal for immunotherapy of cancer · 2020Article
- Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy.Journal of Cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The microbiota plays a key role in regulating the innate and adaptive immune system. Herein, we review the immunological aspects of the microbiota in tumor immunity in mice and man, with a focus on toll-like receptor (TLR) agonists, vaccines, checkpoint modulators, chemotherapy, and adoptive T cell transfer (ACT) therapies. We propose innovative treatments that may safely harness the microbiota to enhance T cell-based therapies in cancer patients. Finally, we highlight recent developments in tumor immunotherapy, particularly novel ways to modulate the microbiome and memory T cell responses to human malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.